Litigation Details for Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Docket	1:23-cv-00879	Date Filed	2023-08-10
Court	District Court, D. Delaware	Date Terminated	2026-04-28
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To	Christopher J. Burke
Parties	DEXCEL PHARMA TECHNOLOGIES LIMITED
Patents	7,214,695; 7,214,696; 9,770,441
Attorneys	Daniel Taylor
Firms	Young, Conaway, Stargatt & Taylor
Link to Docket	External link to docket

Details for Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-08-10				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Last updated: July 6, 2026

Pfizer Inc. v. Cipla Limited (1:23-cv-00879): Litigation Summary, Claims at Issue, and Market Impact

Executive summary: The case Pfizer Inc. v. Cipla Limited, 1:23-cv-00879, is a U.S. patent infringement dispute tied to Pfizer’s FDA pipeline and/or approved-product patent estate and Cipla’s generic development. A litigation timeline, asserted patent numbers, claim construction posture, and the specific filing link to the relevant FDA regulatory submission determine whether Cipla faces immediate injunction risk or primarily monetary exposure through damages and potential carve-outs. Without the docket text showing (1) the specific asserted patents, (2) the scheduled relief (injunction vs. damages), (3) the filing basis (Paragraph IV vs. other), and (4) the current motion/claim status, a complete and accurate litigation analysis cannot be produced.

What patent claims are asserted in Pfizer v. Cipla 1:23-cv-00879?

A litigation summary requires the asserted patent list and the specific asserted claims (often shown in the complaint and the infringement contentions). These data determine:

• Whether the dispute is focused on active ingredient manufacturing, formulation, method of use, combination claims, or polymorph/particle-size/crystalline form.
• The likely design-around paths for Cipla (for example, switching strength, salt form, polymorph, or dosing regimen).
• The risk that the court will treat key limitations as structural (harder to design around) versus functional (easier to argue non-infringement).

How do infringement allegations typically map to Orange Book-listed patents?

In U.S. generic disputes, the complaint usually tracks Orange Book patents tied to:

• drug substance and drug product (formulation, coatings, excipients),
• methods of use (therapeutic regimen claims),
• and manufacturing processes (less common for generics but can appear).

But the case-specific mapping depends on the docket record.

When did Pfizer sue Cipla in 1:23-cv-00879, and what are the key procedural milestones?

A complete litigation timeline requires dates from the docket, including:

• complaint filing date,
• Cipla’s answer and defenses,
• any amended pleadings,
• scheduling order,
• infringement contentions and invalidity contentions,
• Markman claim construction dates,
• summary judgment briefing,
• trial dates or settlement conferences,
• and any dismissal, consent judgment, or stipulation of infringement.

Without docket entries and dates, an accurate timeline cannot be stated.

What is the typical schedule in Hatch-Waxman patent cases like this?

For Hatch-Waxman matters, the schedule often includes:

• early case management and contentions,
• claim construction (Markman),
• expert disclosures,
• dispositive motions (e.g., indefiniteness, lack of enablement, anticipation/obviousness),
• and a bench or jury trial or settlement-based resolution.

Case-specific deadlines control, and they are not provided.

Is this a Paragraph IV certification dispute, and what does it imply for generic entry risk?

Generic entry risk hinges on the FDA certification posture and whether the case is anchored to:

• Paragraph IV (non-infringement and/or invalidity of one or more Orange Book patents),
• a non-Paragraph IV pathway (less common for the standard Hatch-Waxman patent infringement workflow).

A paragraph-IV framing also determines:

• the likely availability of 30-month stay protection,
• the timing of any court injunction exposure under 35 U.S.C. § 271(e)(4),
• and the leverage position in settlement negotiations.

Case-specific certification details are not available in the prompt.

What is the status of claim construction (Markman) in 1:23-cv-00879?

Patent claim interpretation drives infringement and validity outcomes. A litigation analysis must state:

• whether Markman has occurred,
• what terms were construed,
• whether constructions favor Pfizer’s reading (narrowing design-around freedom for Cipla) or favor Cipla’s reading (broadening ambiguity or excluding key limitations).

Without the docket’s Markman rulings or orders, a claim-construction-based analysis cannot be accurate.

How strong is Pfizer’s patent estate versus Cipla’s invalidity defenses in 1:23-cv-00879?

A rigorous assessment requires:

• the invalidity theories asserted (35 U.S.C. §§ 102/103/112, inequitable conduct),
• the cited prior art and how it maps to the asserted claims,
• any procedural posture (pleading-stage, summary judgment, trial).

This depends on:

• invalidity contentions,
• expert reports,
• and any dispositive motion results.

Those elements are not provided.

Has any court ruled on injunction, preliminary relief, or damages in 1:23-cv-00879?

Outcome categories that must be confirmed from docket orders:

• denial or grant of a preliminary injunction (rare but outcome-defining),
• infringement rulings (partial or full),
• validity rulings (invalidation or survival of patents),
• stay or dismissal due to mootness, license, or covenant not to sue,
• final judgment.

Without order data, an injunction-or-damages analysis cannot be stated.

What settlements or consent judgments affect market exclusivity in 1:23-cv-00879?

Settlements can convert litigation into:

• a stipulated infringement finding for limited periods,
• a court-supervised judgment with delayed entry dates,
• license terms (royalty-bearing entry),
• or a covenant not to sue.

A market-impact analysis requires:

• the settlement date,
• the permitted launch date (often tied to patent expiry),
• and the scope (which strengths, dosage forms, or patient subsets).

Settlement terms are not provided.

Which FDA drug product and which Cipla ANDA (or other submission) are at issue?

A litigation analysis for a generic case must tie:

• the lawsuit to the specific FDA NDA/ANDA/BLA,
• the drug name, dosage form, strength, and route,
• and the relevant FDA approval status.

This link typically appears in:

• complaint allegations describing the ANDA,
• references to FDA letter dates,
• or attachments in the docket.

The prompt does not identify the asserted product.

What is the Orange Book status for the patents at issue in Pfizer v. Cipla 1:23-cv-00879?

An Orange Book status section requires the:

• Orange Book patent numbers,
• patent expiration dates,
• exclusivity expiration dates (5-year/3-year data exclusivity or other),
• and whether the patents are listed as method-of-use, drug substance, or drug product.

Without knowing the product and patent numbers, Orange Book status cannot be computed.

What is the commercial and timing impact of 1:23-cv-00879 on generic entry?

The timing impact is usually driven by:

• remaining patent life on asserted patents,
• whether a 30-month stay is in effect and when it expires,
• whether courts shorten or extend practical entry time through injunction.

A credible business impact assessment needs:

• specific expiration/expiry dates,
• the certification date,
• and whether any patents were found invalid or non-infringed.

These inputs are absent.

How does Cipla’s design-around strategy typically work in similar Pfizer patent cases?

In Pfizer-style Hatch-Waxman disputes, design-around often targets:

• different polymorph/crystal form,
• different manufacturing process parameters,
• different particle size distribution,
• alternative formulation excipient systems,
• different dosage regimen (when method-of-use claims exist).

A case-specific design-around mapping requires:

• Cipla’s proposed product characteristics,
• claim limitations in asserted patents,
• and court/ITC-style findings on equivalence (if asserted).

No case details are included.

What are the jurisdiction and procedural risks for either party in the Northern District or transfer venue?

Venue and jurisdiction influence:

• local rules,
• typical speed to Markman,
• magistrate management,
• and scheduling predictability.

But the prompt provides only the case number: 1:23-cv-00879. Without the court division/assignment, no accurate jurisdictional analysis can be completed.

Key Takeaways

• A complete litigation summary for Pfizer Inc. v. Cipla Limited, 1:23-cv-00879 requires docket-specific facts: asserted patents/claims, FDA submission linkage, procedural posture, and any court orders on infringement, validity, injunction, or settlement.
• Those required case facts are not provided in the prompt, so a definitive claims-and-outcome analysis cannot be produced.
• Any market-exclusivity and generic-entry impact calculation depends on the Orange Book patent list and their expiration/exclusivity dates, which also are not identified here.

FAQs

1. What patents are asserted in Pfizer v. Cipla 1:23-cv-00879?
2. Is Pfizer v. Cipla 1:23-cv-00879 based on an ANDA Paragraph IV certification?
3. What is the Markman status in Pfizer v. Cipla 1:23-cv-00879 and what claims were construed?
4. Has the court granted any preliminary injunction or dispositive relief in Pfizer v. Cipla 1:23-cv-00879?
5. What Orange Book patents and expiration dates are tied to the asserted claims in Pfizer v. Cipla 1:23-cv-00879?

References

1. (No cited sources provided in the prompt.)